Literature DB >> 9052415

Role of glucose-6-phosphate dehydrogenase inhibition in the antiproliferative effects of dehydroepiandrosterone on human breast cancer cells.

M Di Monaco1, A Pizzini, V Gatto, L Leonardi, M Gallo, E Brignardello, G Boccuzzi.   

Abstract

Epidemiological and experimental studies suggest that dehydroepiandrosterone (DHEA) exerts a protective effect against breast cancer. It has been proposed that the non-competitive inhibition of glucose-6-phosphate dehydrogenase (G6PD) contributes to DHEA antitumor action. We evaluated the effects of DHEA on G6PD activity and on the in vitro proliferation of two human breast cancer cell lines, MCF-7 (steroid receptor positive) and MDA-MB-231 (steroid receptor negative), in a serum-free assay. DHEA inhibition of G6PD was only found to occur at concentrations above 10 microM; at these high concentrations, the growth curve was parallel to the enzyme inhibition curve in both cell lines. In contrast, at concentrations in the in vivo breast tissue concentration range, neither cell growth nor enzyme activity was inhibited. The results failed to confirm DHEA's putative anti-tumor action on breast cancer through G6PD inhibition, as the enzyme blockade only becomes apparent at pharmacological concentrations of the steroid.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9052415      PMCID: PMC2063293          DOI: 10.1038/bjc.1997.102

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  26 in total

1.  Abnormal excretion of urinary steroids by women with early breast cancer.

Authors:  R D BULBROOK; J L HAYWARD; C C SPICER; B S THOMAS
Journal:  Lancet       Date:  1962-12-15       Impact factor: 79.321

2.  Inhibition of spontaneous breast cancer formation in female C3H(Avy/a) mice by long-term treatment with dehydroepiandrosterone.

Authors:  A G Schwartz
Journal:  Cancer Res       Date:  1979-03       Impact factor: 12.701

3.  Interaction of delta-5-androstene-3beta, 17beta-diol with estradiol and dihydrotestosterone receptors in human myometrial and mammary cancer tissue.

Authors:  J Poortman; J A Prenen; F Schwarz; J H Thijssen
Journal:  J Clin Endocrinol Metab       Date:  1975-03       Impact factor: 5.958

4.  Plasma dehydroepiandrosterone sulphate levels in patients with benign and malignant breast disease.

Authors:  B Brownsey; E H Cameron; K Griffiths; E N Gleave; A P Forrest; H Campbell
Journal:  Eur J Cancer       Date:  1972-02       Impact factor: 9.162

5.  Studies on the sulphate esters of dehydroepiandrosterone and androsterone in the blood of women with breast cancer.

Authors:  D Y Wang; R D Bulbrook; M Herian; J L Hayward
Journal:  Eur J Cancer       Date:  1974-08       Impact factor: 9.162

6.  Inhibition of 7,12-dimethylbenz(a)anthracene-induced skin papillomas and carcinomas by dehydroepiandrosterone and 3-beta-methylandrost-5-en-17-one in mice.

Authors:  L L Pashko; G C Hard; R J Rovito; J R Williams; E L Sobel; A G Schwartz
Journal:  Cancer Res       Date:  1985-01       Impact factor: 12.701

7.  Endogenous concentration and subcellular distribution of androgens in normal and malignant human breast tissue.

Authors:  A A van Landeghem; J Poortman; M Nabuurs; J H Thijssen
Journal:  Cancer Res       Date:  1985-06       Impact factor: 12.701

8.  Modulatory effect of glucose-6-phosphate dehydrogenase deficiency on benzo(a)pyrene toxicity and transforming activity for in vitro-cultured human skin fibroblasts.

Authors:  F Feo; L Pirisi; R Pascale; L Daino; S Frassetto; R Garcea; L Gaspa
Journal:  Cancer Res       Date:  1984-08       Impact factor: 12.701

9.  Inhibition of 7,12-dimethylbenz[a]anthracene- and urethan-induced lung tumor formation in A/J mice by long-term treatment with dehydroepiandrosterone.

Authors:  A G Schwartz; R H Tannen
Journal:  Carcinogenesis       Date:  1981       Impact factor: 4.944

10.  Abnormal 24-hr mean plasma concentrations of dehydroisoandrosterone and dehydroisoandrosterone sulfate in women with primary operable breast cancer.

Authors:  B Zumoff; J Levin; R S Rosenfeld; M Markham; G W Strain; D K Fukushima
Journal:  Cancer Res       Date:  1981-09       Impact factor: 12.701

View more
  17 in total

1.  Adaptive responses and apoptosis in endothelial cells exposed to carbon monoxide.

Authors:  S R Thom; D Fisher; Y A Xu; K Notarfrancesco; H Ischiropoulos
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-01       Impact factor: 11.205

2.  Glucose-6-Phosphate Dehydrogenase Is Not Essential for K-Ras-Driven Tumor Growth or Metastasis.

Authors:  Jonathan M Ghergurovich; Mark Esposito; Zihong Chen; Joshua Z Wang; Vrushank Bhatt; Taijin Lan; Eileen White; Yibin Kang; Jessie Yanxiang Guo; Joshua D Rabinowitz
Journal:  Cancer Res       Date:  2020-07-13       Impact factor: 12.701

3.  Paclitaxel combined with inhibitors of glucose and hydroperoxide metabolism enhances breast cancer cell killing via H2O2-mediated oxidative stress.

Authors:  Tanja Hadzic; Nükhet Aykin-Burns; Yueming Zhu; Mitchell C Coleman; Katie Leick; Geraldine M Jacobson; Douglas R Spitz
Journal:  Free Radic Biol Med       Date:  2010-01-18       Impact factor: 7.376

Review 4.  Dehydroepiandrosterone on metabolism and the cardiovascular system in the postmenopausal period.

Authors:  Caio Jordão Teixeira; Katherine Veras; Carla Roberta de Oliveira Carvalho
Journal:  J Mol Med (Berl)       Date:  2019-11-12       Impact factor: 4.599

5.  SIRT2 activates G6PD to enhance NADPH production and promote leukaemia cell proliferation.

Authors:  Shuang-Nian Xu; Tian-Shi Wang; Xi Li; Yi-Ping Wang
Journal:  Sci Rep       Date:  2016-09-02       Impact factor: 4.379

6.  Inhibition of Glucose-6-Phosphate Dehydrogenase Reverses Cisplatin Resistance in Lung Cancer Cells via the Redox System.

Authors:  Weipeng Hong; Peiheng Cai; Chuncao Xu; Di Cao; Weibang Yu; Zhongxiang Zhao; Min Huang; Jing Jin
Journal:  Front Pharmacol       Date:  2018-01-31       Impact factor: 5.810

7.  Role of genetic changes in the progression of cardiovascular diseases.

Authors:  S A Sheweita; H Baghdadi; A R Allam
Journal:  Int J Biomed Sci       Date:  2011-12

8.  Dehydroepiandrosterone inhibits cell proliferation and improves viability by regulating S phase and mitochondrial permeability in primary rat Leydig cells.

Authors:  Lin Liu; Dian Wang; Longlong Li; Xiao Ding; Haitian Ma
Journal:  Mol Med Rep       Date:  2016-05-24       Impact factor: 2.952

9.  A new inhibitor of glucose-6-phosphate dehydrogenase blocks pentose phosphate pathway and suppresses malignant proliferation and metastasis in vivo.

Authors:  Luigi Mele; Francesca Paino; Federica Papaccio; Tarik Regad; David Boocock; Paola Stiuso; Angela Lombardi; Davide Liccardo; Gabriella Aquino; Antonio Barbieri; Claudio Arra; Clare Coveney; Marcella La Noce; Gianpaolo Papaccio; Michele Caraglia; Virginia Tirino; Vincenzo Desiderio
Journal:  Cell Death Dis       Date:  2018-05-01       Impact factor: 8.469

10.  A small molecule G6PD inhibitor reveals immune dependence on pentose phosphate pathway.

Authors:  Jonathan M Ghergurovich; Juan C García-Cañaveras; Joshua Wang; Emily Schmidt; Zhaoyue Zhang; Tara TeSlaa; Harshel Patel; Li Chen; Emily C Britt; Marta Piqueras-Nebot; Mari Carmen Gomez-Cabrera; Agustín Lahoz; Jing Fan; Ulf H Beier; Hahn Kim; Joshua D Rabinowitz
Journal:  Nat Chem Biol       Date:  2020-05-11       Impact factor: 15.040

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.